Tag: aromatase inhibitor

1. A five-year extension of anastrozole treatment was shown not to provide additional benefit compared to a two-year extension in postmenopausal women with hormone-receptor-positive breast cancer. 2. Anastrozole treatment prolongation was shown to increase the risk of bone fracture. Evidence Rating Level: 1 (Excellent) Study Rundown: The most prevalent molecular subtype of...
1. In a phase II trial of 35 women with advanced endometrial cancer, combination therapy with aromatase inhibitor (letrozole) and mTOR inhibitor (everolimus) demonstrated a high clinical benefit rate. Evidence Rating Level: 2 (Good) Study Rundown: Endometrial cancer (EC) is the most common gynecological malignancy in the United States with over...
1. Aerobic and resistance exercise regimen improved arthralgia-related pain severity in breast cancer survivors on aromatase inhibitors compared to those on usual care. Evidence Rating Level: 1 (Excellent) Study Rundown: Aromatase inhibitors (AIs) are considered the first-line therapy for post-menopausal women with hormone receptor positive breast cancer. However, previous studies have...
1. In a phase I trial, ODM-201 was well tolerated up to 1800mg per day in prostate cancer patients, without reaching the maximum tolerated dose. 2. In a phase II trial, up to 33% of patients randomized to ODM-201 had a 50% or greater decrease in serum PSA at 12...